RYTM Latest Headlines

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)

at www.tipranks.com (Mon, 2-Mar 7:31 AM)

Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity

at www.tipranks.com (Mon, 2-Mar 6:44 AM)

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies

at www.tipranks.com (Fri, 27-Feb 11:56 AM)

Rhythm Pharmaceuticals (RYTM) Receives a Buy from RBC Capital

at www.tipranks.com (Fri, 27-Feb 7:23 AM)

Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate

at seekingalpha.com (Thu, 26-Feb 3:09 PM)

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)

at www.tipranks.com (Thu, 26-Feb 2:50 PM)

Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target

at www.tipranks.com (Thu, 26-Feb 1:15 PM)

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07, revenue of $57.3M beats by $1.09M

at seekingalpha.com (Thu, 26-Feb 7:15 AM)

Rhythm Pharmaceuticals to Reveal Preliminary Phase 2 Results for Setmelanotide in Prader-Willi Syndrome

Market Chameleon (Thu, 11-Dec 10:31 AM)

Setmelanotide Shows Promising Early Results in Prader-Willi Syndrome: Phase 2 Data Signal Efficacy and Support Advancement

Market Chameleon (Thu, 11-Dec 9:00 AM)